Values First Advisors Inc. Invests $293,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Values First Advisors Inc. acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,399 shares of the biopharmaceutical company’s stock, valued at approximately $293,000.

Several other hedge funds have also bought and sold shares of the stock. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 5.9% in the 3rd quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after buying an additional 300,406 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Celldex Therapeutics by 0.8% in the first quarter. BlackRock Inc. now owns 3,250,638 shares of the biopharmaceutical company’s stock worth $116,958,000 after buying an additional 25,922 shares during the period. State Street Corp raised its position in Celldex Therapeutics by 20.4% during the 2nd quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock valued at $87,050,000 after purchasing an additional 546,124 shares during the last quarter. Kynam Capital Management LP raised its position in shares of Celldex Therapeutics by 23.1% in the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock worth $88,064,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Celldex Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,618,504 shares of the biopharmaceutical company’s stock worth $72,061,000 after purchasing an additional 20,688 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Guggenheim upped their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. TD Cowen initiated coverage on shares of Celldex Therapeutics in a research note on Wednesday, December 20th. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $66.00.

Celldex Therapeutics Trading Up 0.4 %

Shares of CLDX stock traded up $0.18 during trading hours on Thursday, reaching $41.97. 579,320 shares of the company’s stock were exchanged, compared to its average volume of 958,280. The stock’s fifty day moving average price is $41.20 and its two-hundred day moving average price is $34.38. The stock has a market cap of $2.35 billion, a PE ratio of -14.42 and a beta of 1.52. Celldex Therapeutics, Inc. has a 1 year low of $22.11 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. The firm had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. On average, equities analysts expect that Celldex Therapeutics, Inc. will post -2.93 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.